Wells Fargo’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-26,565
| Closed | -$98K | – | 6749 |
|
|
2017
Q4 | $98K | Buy |
26,565
+24,109
| +982% | +$98.7K | ﹤0.01% | 5322 |
|
|
2017
Q3 | $10K | Buy |
2,456
+2,406
| +4,812% | +$9.2K | ﹤0.01% | 5888 |
|
|
2017
Q2 | $0 | Buy |
50
+11
| +28% | +$44 | ﹤0.01% | 6635 |
|
|
2017
Q1 | $0 | Sell |
39
-500
| -93% | -$2.1K | ﹤0.01% | 6674 |
|
|
2016
Q4 | $2K | Sell |
539
-3
| -0.6% | -$19 | ﹤0.01% | 6123 |
|
|
2016
Q3 | $5K | Sell |
542
-227
| -30% | -$1.61K | ﹤0.01% | 5932 |
|
|
2016
Q2 | $4K | Sell |
769
-7,533
| -91% | -$51.1K | ﹤0.01% | 5875 |
|
|
2016
Q1 | $63K | Buy |
8,302
+914
| +12% | +$7.04K | ﹤0.01% | 5131 |
|
|
2015
Q4 | $98K | Buy |
7,388
+4,179
| +130% | +$72K | ﹤0.01% | 4915 |
|
|
2015
Q3 | $53K | Sell |
3,209
-5,872
| -65% | -$120K | ﹤0.01% | 5248 |
|
|
2015
Q2 | $204K | Buy |
9,081
+7,971
| +718% | +$126K | ﹤0.01% | 4602 |
|
|
2015
Q1 | $11K | Sell |
1,110
-2,996
| -73% | -$29.4K | ﹤0.01% | 5610 |
|
|
2014
Q4 | $46K | Buy |
4,106
+81
| +2% | +$879 | ﹤0.01% | 5039 |
|
|
2014
Q3 | $46K | Sell |
4,025
-296
| -7% | -$4.52K | ﹤0.01% | 4970 |
|
|
2014
Q2 | $84K | Sell |
4,321
-3,948
| -48% | -$69.7K | ﹤0.01% | 4754 |
|
|
2014
Q1 | $148K | Buy |
8,269
+8,227
| +19,588% | +$135K | ﹤0.01% | 4479 |
|
|
2013
Q4 | $0 | Sell |
42
-1,859
| -98% | -$20.8K | ﹤0.01% | 6066 |
|
|
2013
Q3 | $24K | Buy |
1,901
+1,266
| +199% | +$13.3K | ﹤0.01% | 4912 |
|
|
2013
Q2 | $6K | Buy |
+635
| New | +$8.16K | ﹤0.01% | 5200 |
|
Wells Fargo's CASC Position: Q1 2018 in Review
Wells Fargo sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 26,565 shares — an estimated $98K sold.
Wells Fargo first reported a position in CASC in Q2 2013 and held it in 19 quarters. The position peaked at $204K in Q2 2015. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- Wells Fargo reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- Wells Fargo sold 26,565 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $98K.
- Wells Fargo first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 19 quarters.
- Wells Fargo's Cascadian Therapeutics, Inc. position peaked at $204K in Q2 2015.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on Wells Fargo's 13F filing for Q1 2018, filed 2 May 2018.